FDA Brief

Warning letters Devices

FDA warning letter to

IsoTis OrthoBiologics, Inc.

High riskIssued Feb 24Posted Mar 24Center for Devices and Radiological Health

IsoTis OrthoBiologics in Irvine, CA failed to properly fix and assess possible particulate contamination in its Accell bone filler devices, FDA says.

What happened

FDA inspected the Irvine, CA facility from October 6 to October 17, 2025. Investigators found that a propeller blade was contacting the bottom of the vessel used to demineralize bone tissue, possibly shedding particles into the demineralized bone matrix, and that the company closed its corrective action (CAPA) without evidence the contamination had stopped or an assessment of already distributed product. The company's own manager said particles may have been present since the process began in 2008, potentially affecting over (b)(4) devices, and its risk files were never updated for this hazard.

What FDA found

  1. The company closed a corrective action about possible particulate contamination without showing the problem was fixed or checking the impact on devices already shipped.

    21 CFR 820.100(a)
  2. The company made a major design change to its demineralization press but did not revalidate the process, treating the press as a tool rather than equipment.

    21 CFR 820.75(c)
  3. The company did not update its risk analysis (FMEAs and hazard analysis) after learning its own manufacturing could shed particles, and did not reassess severity or probability.

    21 CFR 820.30(g)
  4. The health hazard evaluation dismissed complaints, treated particle-related inflammation as normal post-surgical inflammation, rated severity too low, and did not test distributed product for particles or assess biocompatibility.

What FDA wants

The company must reply in writing within 15 business days describing the specific corrections and corrective actions taken, how it will prevent recurrence, and a timetable for anything not yet finished. Any corrective actions must follow the new Quality Management System Regulation (QMSR) that took effect February 2, 2026.

Who should pay attention

  • surgeons and hospitals that implanted Accell, OrthoBlast II or DynaGraft II bone graft products
  • distributors and brands selling IsoTis bone void fillers
  • companies buying demineralized bone matrix from contract manufacturers

This is a summary. Read the original letter on fda.gov.

IsoTis OrthoBiologics, Inc.'s FDA history

Recalls in the last 12 months

Aug 5 Class II IsoTis OrthoBiologics, Inc.
Device
OsteoBallast, 45 x 17.5 mm (SeaSpine Brand), REF: 56800095. Ballast, 45 x 17.5 mm (IsoTis Brand), REF: 02-8000-095
Demineralized bone matrix (DBM) in resorbable mesh indicated for use with autograft as a bone graft extender in the posterolateral spine and pelvis, were filled with approx. 4.5 cc DBM (fill for 45 ¿ 11 mm configuration) instead of approx. 7.5 cc DBM (fill for 45 ¿ 17.5 mm configuration), which may lead to delayed fusion, incomplete fusion, pseudarthrosis, or lack of bone ingrowth.

Full company page

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Jubilant HollisterStier General Partnership

    FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

    High risk
  3. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

    FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

    High risk
  4. Sato Pharmaceutical Co., Ltd.

    FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

    High risk